Global ADHD Treatment Market

ADHD Treatment Comprehensive Study by Type (Methylphenidate, Lisdexamfetamine, Dexamfetamine, Atomoxetine, Guanfacine, Others), Treatment (Medications, Behavior Therapy, Counselling, Education Services, Others), End-User (Retail Pharmacy, Hospital Pharmacy, Clinics), Age (Adult (Aged 18 and above), Children) Players and Region - Global Market Outlook to 2030

ADHD Treatment Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 20.3%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About ADHD Treatment
The most common neurodevelopmental illness in children is attention deficit hyperactivity disorder (ADHD). ADHD is typically diagnosed in childhood and persists into adulthood. Children with ADHD may daydream excessively, forget or lose things, have problems resisting temptation, have trouble taking turns, have difficulty getting along with others, be extremely energetic, and have difficulty paying attention. Stimulant and non-stimulant medications are used to treat attention deficit hyperactivity disorder (ADHD).

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
CAGR20.3%


Mergers and acquisitions, expansions, investments, new service launches, and collaborations are among the companies' favoured techniques for exploring the market. Players are expanding and acquiring businesses in new geographies in order to get a competitive edge through synergy. The major key players are contributing there share for increasing company growth. Manufacturers are aiming their products at both children and adults with ADHD. Certain prescriptions are flavoured to make them more appealing to children, whereas the purpose for adults is to offer a long-lasting effect so that they don't have to take as many tablets each day. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global ADHD Treatment market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Amneal Pharmaceuticals, Inc (United States), Eli Lilly and Company (United States), Novartis International AG (Switzerland), Janssen Pharmaceuticals, Inc (Belgium), Mayo Clinic (United States), RespireRx Pharmaceuticals Inc (United States), Otsuka Pharmaceutical Co., Ltd (Japan), Neos Therapeutics, Inc. (United States), Takeda Pharmaceutical Company Limited (Japan) and GlaxoSmithKline plc (United Kingdom) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Noven Pharmaceuticals, Inc (United States) and Purdue Pharma L.P. (United States).

Segmentation Overview
AMA Research has segmented the market of Global ADHD Treatment market by Type (Methylphenidate, Lisdexamfetamine, Dexamfetamine, Atomoxetine, Guanfacine and Others) and Region.



On the basis of geography, the market of ADHD Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Treatment, the sub-segment i.e. Medications will boost the ADHD Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End-User, the sub-segment i.e. Retail Pharmacy will boost the ADHD Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Age, the sub-segment i.e. Adult (Aged 18 and above) will boost the ADHD Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increasing demand of Azstarys which is stimulant medication

Market Growth Drivers:
Rising Prevalence of ADHD Treatment, Growing Clinical Trials by Companies and Academic Institutes and Need for Continuous Cognitive Improvement in Students

Challenges:
New alternative treatment methods are launched and Inappropriate Funding Procedures

Restraints:
Side-Effects Associated with ADHD Drugs and High Cost of ADHD Drugs

Opportunities:
Increasing the Product's Marketing and Partnership Agreements

Market Leaders and their expansionary development strategies
In May 2021 WebMD Health Corp., an Internet Brands company and a leader in health information services for consumers and healthcare professionals (HCPs), today announced the acquisition of ADDitude, a multi-channel platform supporting people with attention deficit hyperactivity disorder (ADHD), their caregivers, and professionals in the ADHD treatment space.
In 2021, The US Food and Drug Administration approved two new ADHD medications in the spring. Qelbree is a nonstimulant drug, while Azstarys is a stimulant. Both are appropriate for children aged six and up.


Key Target Audience
Manufacturing, Providers, Suppliers and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Methylphenidate
  • Lisdexamfetamine
  • Dexamfetamine
  • Atomoxetine
  • Guanfacine
  • Others
By Treatment
  • Medications
  • Behavior Therapy
  • Counselling
  • Education Services
  • Others

By End-User
  • Retail Pharmacy
  • Hospital Pharmacy
  • Clinics

By Age
  • Adult (Aged 18 and above)
  • Children

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Prevalence of ADHD Treatment
      • 3.2.2. Growing Clinical Trials by Companies and Academic Institutes
      • 3.2.3. Need for Continuous Cognitive Improvement in Students
    • 3.3. Market Challenges
      • 3.3.1. New alternative treatment methods are launched
      • 3.3.2. Inappropriate Funding Procedures
    • 3.4. Market Trends
      • 3.4.1. Increasing demand of Azstarys which is stimulant medication
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global ADHD Treatment, by Type, Treatment, End-User, Age and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global ADHD Treatment (Value)
      • 5.2.1. Global ADHD Treatment by: Type (Value)
        • 5.2.1.1. Methylphenidate
        • 5.2.1.2. Lisdexamfetamine
        • 5.2.1.3. Dexamfetamine
        • 5.2.1.4. Atomoxetine
        • 5.2.1.5. Guanfacine
        • 5.2.1.6. Others
      • 5.2.2. Global ADHD Treatment by: Treatment (Value)
        • 5.2.2.1. Medications
        • 5.2.2.2. Behavior Therapy
        • 5.2.2.3. Counselling
        • 5.2.2.4. Education Services
        • 5.2.2.5. Others
      • 5.2.3. Global ADHD Treatment by: End-User (Value)
        • 5.2.3.1. Retail Pharmacy
        • 5.2.3.2. Hospital Pharmacy
        • 5.2.3.3. Clinics
      • 5.2.4. Global ADHD Treatment by: Age (Value)
        • 5.2.4.1. Adult (Aged 18 and above)
        • 5.2.4.2. Children
      • 5.2.5. Global ADHD Treatment Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Australia
          • 5.2.5.2.6. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global ADHD Treatment (Volume)
      • 5.3.1. Global ADHD Treatment by: Type (Volume)
        • 5.3.1.1. Methylphenidate
        • 5.3.1.2. Lisdexamfetamine
        • 5.3.1.3. Dexamfetamine
        • 5.3.1.4. Atomoxetine
        • 5.3.1.5. Guanfacine
        • 5.3.1.6. Others
      • 5.3.2. Global ADHD Treatment by: Treatment (Volume)
        • 5.3.2.1. Medications
        • 5.3.2.2. Behavior Therapy
        • 5.3.2.3. Counselling
        • 5.3.2.4. Education Services
        • 5.3.2.5. Others
      • 5.3.3. Global ADHD Treatment by: End-User (Volume)
        • 5.3.3.1. Retail Pharmacy
        • 5.3.3.2. Hospital Pharmacy
        • 5.3.3.3. Clinics
      • 5.3.4. Global ADHD Treatment by: Age (Volume)
        • 5.3.4.1. Adult (Aged 18 and above)
        • 5.3.4.2. Children
      • 5.3.5. Global ADHD Treatment Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Australia
          • 5.3.5.2.6. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global ADHD Treatment (Price)
      • 5.4.1. Global ADHD Treatment by: Type (Price)
  • 6. ADHD Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Amneal Pharmaceuticals, Inc (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Eli Lilly and Company (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Novartis International AG (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Janssen Pharmaceuticals, Inc (Belgium)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Mayo Clinic (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. RespireRx Pharmaceuticals Inc (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Otsuka Pharmaceutical Co., Ltd (Japan)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Neos Therapeutics, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Takeda Pharmaceutical Company Limited (Japan)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. GlaxoSmithKline plc (United Kingdom)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global ADHD Treatment Sale, by Type, Treatment, End-User, Age and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global ADHD Treatment (Value)
      • 7.2.1. Global ADHD Treatment by: Type (Value)
        • 7.2.1.1. Methylphenidate
        • 7.2.1.2. Lisdexamfetamine
        • 7.2.1.3. Dexamfetamine
        • 7.2.1.4. Atomoxetine
        • 7.2.1.5. Guanfacine
        • 7.2.1.6. Others
      • 7.2.2. Global ADHD Treatment by: Treatment (Value)
        • 7.2.2.1. Medications
        • 7.2.2.2. Behavior Therapy
        • 7.2.2.3. Counselling
        • 7.2.2.4. Education Services
        • 7.2.2.5. Others
      • 7.2.3. Global ADHD Treatment by: End-User (Value)
        • 7.2.3.1. Retail Pharmacy
        • 7.2.3.2. Hospital Pharmacy
        • 7.2.3.3. Clinics
      • 7.2.4. Global ADHD Treatment by: Age (Value)
        • 7.2.4.1. Adult (Aged 18 and above)
        • 7.2.4.2. Children
      • 7.2.5. Global ADHD Treatment Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Australia
          • 7.2.5.2.6. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global ADHD Treatment (Volume)
      • 7.3.1. Global ADHD Treatment by: Type (Volume)
        • 7.3.1.1. Methylphenidate
        • 7.3.1.2. Lisdexamfetamine
        • 7.3.1.3. Dexamfetamine
        • 7.3.1.4. Atomoxetine
        • 7.3.1.5. Guanfacine
        • 7.3.1.6. Others
      • 7.3.2. Global ADHD Treatment by: Treatment (Volume)
        • 7.3.2.1. Medications
        • 7.3.2.2. Behavior Therapy
        • 7.3.2.3. Counselling
        • 7.3.2.4. Education Services
        • 7.3.2.5. Others
      • 7.3.3. Global ADHD Treatment by: End-User (Volume)
        • 7.3.3.1. Retail Pharmacy
        • 7.3.3.2. Hospital Pharmacy
        • 7.3.3.3. Clinics
      • 7.3.4. Global ADHD Treatment by: Age (Volume)
        • 7.3.4.1. Adult (Aged 18 and above)
        • 7.3.4.2. Children
      • 7.3.5. Global ADHD Treatment Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Australia
          • 7.3.5.2.6. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global ADHD Treatment (Price)
      • 7.4.1. Global ADHD Treatment by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. ADHD Treatment: by Type(USD Million)
  • Table 2. ADHD Treatment Methylphenidate , by Region USD Million (2018-2023)
  • Table 3. ADHD Treatment Lisdexamfetamine , by Region USD Million (2018-2023)
  • Table 4. ADHD Treatment Dexamfetamine , by Region USD Million (2018-2023)
  • Table 5. ADHD Treatment Atomoxetine , by Region USD Million (2018-2023)
  • Table 6. ADHD Treatment Guanfacine , by Region USD Million (2018-2023)
  • Table 7. ADHD Treatment Others , by Region USD Million (2018-2023)
  • Table 8. ADHD Treatment: by Treatment(USD Million)
  • Table 9. ADHD Treatment Medications , by Region USD Million (2018-2023)
  • Table 10. ADHD Treatment Behavior Therapy , by Region USD Million (2018-2023)
  • Table 11. ADHD Treatment Counselling , by Region USD Million (2018-2023)
  • Table 12. ADHD Treatment Education Services , by Region USD Million (2018-2023)
  • Table 13. ADHD Treatment Others , by Region USD Million (2018-2023)
  • Table 14. ADHD Treatment: by End-User(USD Million)
  • Table 15. ADHD Treatment Retail Pharmacy , by Region USD Million (2018-2023)
  • Table 16. ADHD Treatment Hospital Pharmacy , by Region USD Million (2018-2023)
  • Table 17. ADHD Treatment Clinics , by Region USD Million (2018-2023)
  • Table 18. ADHD Treatment: by Age(USD Million)
  • Table 19. ADHD Treatment Adult (Aged 18 and above) , by Region USD Million (2018-2023)
  • Table 20. ADHD Treatment Children , by Region USD Million (2018-2023)
  • Table 21. South America ADHD Treatment, by Country USD Million (2018-2023)
  • Table 22. South America ADHD Treatment, by Type USD Million (2018-2023)
  • Table 23. South America ADHD Treatment, by Treatment USD Million (2018-2023)
  • Table 24. South America ADHD Treatment, by End-User USD Million (2018-2023)
  • Table 25. South America ADHD Treatment, by Age USD Million (2018-2023)
  • Table 26. Brazil ADHD Treatment, by Type USD Million (2018-2023)
  • Table 27. Brazil ADHD Treatment, by Treatment USD Million (2018-2023)
  • Table 28. Brazil ADHD Treatment, by End-User USD Million (2018-2023)
  • Table 29. Brazil ADHD Treatment, by Age USD Million (2018-2023)
  • Table 30. Argentina ADHD Treatment, by Type USD Million (2018-2023)
  • Table 31. Argentina ADHD Treatment, by Treatment USD Million (2018-2023)
  • Table 32. Argentina ADHD Treatment, by End-User USD Million (2018-2023)
  • Table 33. Argentina ADHD Treatment, by Age USD Million (2018-2023)
  • Table 34. Rest of South America ADHD Treatment, by Type USD Million (2018-2023)
  • Table 35. Rest of South America ADHD Treatment, by Treatment USD Million (2018-2023)
  • Table 36. Rest of South America ADHD Treatment, by End-User USD Million (2018-2023)
  • Table 37. Rest of South America ADHD Treatment, by Age USD Million (2018-2023)
  • Table 38. Asia Pacific ADHD Treatment, by Country USD Million (2018-2023)
  • Table 39. Asia Pacific ADHD Treatment, by Type USD Million (2018-2023)
  • Table 40. Asia Pacific ADHD Treatment, by Treatment USD Million (2018-2023)
  • Table 41. Asia Pacific ADHD Treatment, by End-User USD Million (2018-2023)
  • Table 42. Asia Pacific ADHD Treatment, by Age USD Million (2018-2023)
  • Table 43. China ADHD Treatment, by Type USD Million (2018-2023)
  • Table 44. China ADHD Treatment, by Treatment USD Million (2018-2023)
  • Table 45. China ADHD Treatment, by End-User USD Million (2018-2023)
  • Table 46. China ADHD Treatment, by Age USD Million (2018-2023)
  • Table 47. Japan ADHD Treatment, by Type USD Million (2018-2023)
  • Table 48. Japan ADHD Treatment, by Treatment USD Million (2018-2023)
  • Table 49. Japan ADHD Treatment, by End-User USD Million (2018-2023)
  • Table 50. Japan ADHD Treatment, by Age USD Million (2018-2023)
  • Table 51. India ADHD Treatment, by Type USD Million (2018-2023)
  • Table 52. India ADHD Treatment, by Treatment USD Million (2018-2023)
  • Table 53. India ADHD Treatment, by End-User USD Million (2018-2023)
  • Table 54. India ADHD Treatment, by Age USD Million (2018-2023)
  • Table 55. South Korea ADHD Treatment, by Type USD Million (2018-2023)
  • Table 56. South Korea ADHD Treatment, by Treatment USD Million (2018-2023)
  • Table 57. South Korea ADHD Treatment, by End-User USD Million (2018-2023)
  • Table 58. South Korea ADHD Treatment, by Age USD Million (2018-2023)
  • Table 59. Australia ADHD Treatment, by Type USD Million (2018-2023)
  • Table 60. Australia ADHD Treatment, by Treatment USD Million (2018-2023)
  • Table 61. Australia ADHD Treatment, by End-User USD Million (2018-2023)
  • Table 62. Australia ADHD Treatment, by Age USD Million (2018-2023)
  • Table 63. Rest of Asia-Pacific ADHD Treatment, by Type USD Million (2018-2023)
  • Table 64. Rest of Asia-Pacific ADHD Treatment, by Treatment USD Million (2018-2023)
  • Table 65. Rest of Asia-Pacific ADHD Treatment, by End-User USD Million (2018-2023)
  • Table 66. Rest of Asia-Pacific ADHD Treatment, by Age USD Million (2018-2023)
  • Table 67. Europe ADHD Treatment, by Country USD Million (2018-2023)
  • Table 68. Europe ADHD Treatment, by Type USD Million (2018-2023)
  • Table 69. Europe ADHD Treatment, by Treatment USD Million (2018-2023)
  • Table 70. Europe ADHD Treatment, by End-User USD Million (2018-2023)
  • Table 71. Europe ADHD Treatment, by Age USD Million (2018-2023)
  • Table 72. Germany ADHD Treatment, by Type USD Million (2018-2023)
  • Table 73. Germany ADHD Treatment, by Treatment USD Million (2018-2023)
  • Table 74. Germany ADHD Treatment, by End-User USD Million (2018-2023)
  • Table 75. Germany ADHD Treatment, by Age USD Million (2018-2023)
  • Table 76. France ADHD Treatment, by Type USD Million (2018-2023)
  • Table 77. France ADHD Treatment, by Treatment USD Million (2018-2023)
  • Table 78. France ADHD Treatment, by End-User USD Million (2018-2023)
  • Table 79. France ADHD Treatment, by Age USD Million (2018-2023)
  • Table 80. Italy ADHD Treatment, by Type USD Million (2018-2023)
  • Table 81. Italy ADHD Treatment, by Treatment USD Million (2018-2023)
  • Table 82. Italy ADHD Treatment, by End-User USD Million (2018-2023)
  • Table 83. Italy ADHD Treatment, by Age USD Million (2018-2023)
  • Table 84. United Kingdom ADHD Treatment, by Type USD Million (2018-2023)
  • Table 85. United Kingdom ADHD Treatment, by Treatment USD Million (2018-2023)
  • Table 86. United Kingdom ADHD Treatment, by End-User USD Million (2018-2023)
  • Table 87. United Kingdom ADHD Treatment, by Age USD Million (2018-2023)
  • Table 88. Netherlands ADHD Treatment, by Type USD Million (2018-2023)
  • Table 89. Netherlands ADHD Treatment, by Treatment USD Million (2018-2023)
  • Table 90. Netherlands ADHD Treatment, by End-User USD Million (2018-2023)
  • Table 91. Netherlands ADHD Treatment, by Age USD Million (2018-2023)
  • Table 92. Rest of Europe ADHD Treatment, by Type USD Million (2018-2023)
  • Table 93. Rest of Europe ADHD Treatment, by Treatment USD Million (2018-2023)
  • Table 94. Rest of Europe ADHD Treatment, by End-User USD Million (2018-2023)
  • Table 95. Rest of Europe ADHD Treatment, by Age USD Million (2018-2023)
  • Table 96. MEA ADHD Treatment, by Country USD Million (2018-2023)
  • Table 97. MEA ADHD Treatment, by Type USD Million (2018-2023)
  • Table 98. MEA ADHD Treatment, by Treatment USD Million (2018-2023)
  • Table 99. MEA ADHD Treatment, by End-User USD Million (2018-2023)
  • Table 100. MEA ADHD Treatment, by Age USD Million (2018-2023)
  • Table 101. Middle East ADHD Treatment, by Type USD Million (2018-2023)
  • Table 102. Middle East ADHD Treatment, by Treatment USD Million (2018-2023)
  • Table 103. Middle East ADHD Treatment, by End-User USD Million (2018-2023)
  • Table 104. Middle East ADHD Treatment, by Age USD Million (2018-2023)
  • Table 105. Africa ADHD Treatment, by Type USD Million (2018-2023)
  • Table 106. Africa ADHD Treatment, by Treatment USD Million (2018-2023)
  • Table 107. Africa ADHD Treatment, by End-User USD Million (2018-2023)
  • Table 108. Africa ADHD Treatment, by Age USD Million (2018-2023)
  • Table 109. North America ADHD Treatment, by Country USD Million (2018-2023)
  • Table 110. North America ADHD Treatment, by Type USD Million (2018-2023)
  • Table 111. North America ADHD Treatment, by Treatment USD Million (2018-2023)
  • Table 112. North America ADHD Treatment, by End-User USD Million (2018-2023)
  • Table 113. North America ADHD Treatment, by Age USD Million (2018-2023)
  • Table 114. United States ADHD Treatment, by Type USD Million (2018-2023)
  • Table 115. United States ADHD Treatment, by Treatment USD Million (2018-2023)
  • Table 116. United States ADHD Treatment, by End-User USD Million (2018-2023)
  • Table 117. United States ADHD Treatment, by Age USD Million (2018-2023)
  • Table 118. Canada ADHD Treatment, by Type USD Million (2018-2023)
  • Table 119. Canada ADHD Treatment, by Treatment USD Million (2018-2023)
  • Table 120. Canada ADHD Treatment, by End-User USD Million (2018-2023)
  • Table 121. Canada ADHD Treatment, by Age USD Million (2018-2023)
  • Table 122. Mexico ADHD Treatment, by Type USD Million (2018-2023)
  • Table 123. Mexico ADHD Treatment, by Treatment USD Million (2018-2023)
  • Table 124. Mexico ADHD Treatment, by End-User USD Million (2018-2023)
  • Table 125. Mexico ADHD Treatment, by Age USD Million (2018-2023)
  • Table 126. ADHD Treatment Sales: by Type(K Units)
  • Table 127. ADHD Treatment Sales Methylphenidate , by Region K Units (2018-2023)
  • Table 128. ADHD Treatment Sales Lisdexamfetamine , by Region K Units (2018-2023)
  • Table 129. ADHD Treatment Sales Dexamfetamine , by Region K Units (2018-2023)
  • Table 130. ADHD Treatment Sales Atomoxetine , by Region K Units (2018-2023)
  • Table 131. ADHD Treatment Sales Guanfacine , by Region K Units (2018-2023)
  • Table 132. ADHD Treatment Sales Others , by Region K Units (2018-2023)
  • Table 133. ADHD Treatment Sales: by Treatment(K Units)
  • Table 134. ADHD Treatment Sales Medications , by Region K Units (2018-2023)
  • Table 135. ADHD Treatment Sales Behavior Therapy , by Region K Units (2018-2023)
  • Table 136. ADHD Treatment Sales Counselling , by Region K Units (2018-2023)
  • Table 137. ADHD Treatment Sales Education Services , by Region K Units (2018-2023)
  • Table 138. ADHD Treatment Sales Others , by Region K Units (2018-2023)
  • Table 139. ADHD Treatment Sales: by End-User(K Units)
  • Table 140. ADHD Treatment Sales Retail Pharmacy , by Region K Units (2018-2023)
  • Table 141. ADHD Treatment Sales Hospital Pharmacy , by Region K Units (2018-2023)
  • Table 142. ADHD Treatment Sales Clinics , by Region K Units (2018-2023)
  • Table 143. ADHD Treatment Sales: by Age(K Units)
  • Table 144. ADHD Treatment Sales Adult (Aged 18 and above) , by Region K Units (2018-2023)
  • Table 145. ADHD Treatment Sales Children , by Region K Units (2018-2023)
  • Table 146. South America ADHD Treatment Sales, by Country K Units (2018-2023)
  • Table 147. South America ADHD Treatment Sales, by Type K Units (2018-2023)
  • Table 148. South America ADHD Treatment Sales, by Treatment K Units (2018-2023)
  • Table 149. South America ADHD Treatment Sales, by End-User K Units (2018-2023)
  • Table 150. South America ADHD Treatment Sales, by Age K Units (2018-2023)
  • Table 151. Brazil ADHD Treatment Sales, by Type K Units (2018-2023)
  • Table 152. Brazil ADHD Treatment Sales, by Treatment K Units (2018-2023)
  • Table 153. Brazil ADHD Treatment Sales, by End-User K Units (2018-2023)
  • Table 154. Brazil ADHD Treatment Sales, by Age K Units (2018-2023)
  • Table 155. Argentina ADHD Treatment Sales, by Type K Units (2018-2023)
  • Table 156. Argentina ADHD Treatment Sales, by Treatment K Units (2018-2023)
  • Table 157. Argentina ADHD Treatment Sales, by End-User K Units (2018-2023)
  • Table 158. Argentina ADHD Treatment Sales, by Age K Units (2018-2023)
  • Table 159. Rest of South America ADHD Treatment Sales, by Type K Units (2018-2023)
  • Table 160. Rest of South America ADHD Treatment Sales, by Treatment K Units (2018-2023)
  • Table 161. Rest of South America ADHD Treatment Sales, by End-User K Units (2018-2023)
  • Table 162. Rest of South America ADHD Treatment Sales, by Age K Units (2018-2023)
  • Table 163. Asia Pacific ADHD Treatment Sales, by Country K Units (2018-2023)
  • Table 164. Asia Pacific ADHD Treatment Sales, by Type K Units (2018-2023)
  • Table 165. Asia Pacific ADHD Treatment Sales, by Treatment K Units (2018-2023)
  • Table 166. Asia Pacific ADHD Treatment Sales, by End-User K Units (2018-2023)
  • Table 167. Asia Pacific ADHD Treatment Sales, by Age K Units (2018-2023)
  • Table 168. China ADHD Treatment Sales, by Type K Units (2018-2023)
  • Table 169. China ADHD Treatment Sales, by Treatment K Units (2018-2023)
  • Table 170. China ADHD Treatment Sales, by End-User K Units (2018-2023)
  • Table 171. China ADHD Treatment Sales, by Age K Units (2018-2023)
  • Table 172. Japan ADHD Treatment Sales, by Type K Units (2018-2023)
  • Table 173. Japan ADHD Treatment Sales, by Treatment K Units (2018-2023)
  • Table 174. Japan ADHD Treatment Sales, by End-User K Units (2018-2023)
  • Table 175. Japan ADHD Treatment Sales, by Age K Units (2018-2023)
  • Table 176. India ADHD Treatment Sales, by Type K Units (2018-2023)
  • Table 177. India ADHD Treatment Sales, by Treatment K Units (2018-2023)
  • Table 178. India ADHD Treatment Sales, by End-User K Units (2018-2023)
  • Table 179. India ADHD Treatment Sales, by Age K Units (2018-2023)
  • Table 180. South Korea ADHD Treatment Sales, by Type K Units (2018-2023)
  • Table 181. South Korea ADHD Treatment Sales, by Treatment K Units (2018-2023)
  • Table 182. South Korea ADHD Treatment Sales, by End-User K Units (2018-2023)
  • Table 183. South Korea ADHD Treatment Sales, by Age K Units (2018-2023)
  • Table 184. Australia ADHD Treatment Sales, by Type K Units (2018-2023)
  • Table 185. Australia ADHD Treatment Sales, by Treatment K Units (2018-2023)
  • Table 186. Australia ADHD Treatment Sales, by End-User K Units (2018-2023)
  • Table 187. Australia ADHD Treatment Sales, by Age K Units (2018-2023)
  • Table 188. Rest of Asia-Pacific ADHD Treatment Sales, by Type K Units (2018-2023)
  • Table 189. Rest of Asia-Pacific ADHD Treatment Sales, by Treatment K Units (2018-2023)
  • Table 190. Rest of Asia-Pacific ADHD Treatment Sales, by End-User K Units (2018-2023)
  • Table 191. Rest of Asia-Pacific ADHD Treatment Sales, by Age K Units (2018-2023)
  • Table 192. Europe ADHD Treatment Sales, by Country K Units (2018-2023)
  • Table 193. Europe ADHD Treatment Sales, by Type K Units (2018-2023)
  • Table 194. Europe ADHD Treatment Sales, by Treatment K Units (2018-2023)
  • Table 195. Europe ADHD Treatment Sales, by End-User K Units (2018-2023)
  • Table 196. Europe ADHD Treatment Sales, by Age K Units (2018-2023)
  • Table 197. Germany ADHD Treatment Sales, by Type K Units (2018-2023)
  • Table 198. Germany ADHD Treatment Sales, by Treatment K Units (2018-2023)
  • Table 199. Germany ADHD Treatment Sales, by End-User K Units (2018-2023)
  • Table 200. Germany ADHD Treatment Sales, by Age K Units (2018-2023)
  • Table 201. France ADHD Treatment Sales, by Type K Units (2018-2023)
  • Table 202. France ADHD Treatment Sales, by Treatment K Units (2018-2023)
  • Table 203. France ADHD Treatment Sales, by End-User K Units (2018-2023)
  • Table 204. France ADHD Treatment Sales, by Age K Units (2018-2023)
  • Table 205. Italy ADHD Treatment Sales, by Type K Units (2018-2023)
  • Table 206. Italy ADHD Treatment Sales, by Treatment K Units (2018-2023)
  • Table 207. Italy ADHD Treatment Sales, by End-User K Units (2018-2023)
  • Table 208. Italy ADHD Treatment Sales, by Age K Units (2018-2023)
  • Table 209. United Kingdom ADHD Treatment Sales, by Type K Units (2018-2023)
  • Table 210. United Kingdom ADHD Treatment Sales, by Treatment K Units (2018-2023)
  • Table 211. United Kingdom ADHD Treatment Sales, by End-User K Units (2018-2023)
  • Table 212. United Kingdom ADHD Treatment Sales, by Age K Units (2018-2023)
  • Table 213. Netherlands ADHD Treatment Sales, by Type K Units (2018-2023)
  • Table 214. Netherlands ADHD Treatment Sales, by Treatment K Units (2018-2023)
  • Table 215. Netherlands ADHD Treatment Sales, by End-User K Units (2018-2023)
  • Table 216. Netherlands ADHD Treatment Sales, by Age K Units (2018-2023)
  • Table 217. Rest of Europe ADHD Treatment Sales, by Type K Units (2018-2023)
  • Table 218. Rest of Europe ADHD Treatment Sales, by Treatment K Units (2018-2023)
  • Table 219. Rest of Europe ADHD Treatment Sales, by End-User K Units (2018-2023)
  • Table 220. Rest of Europe ADHD Treatment Sales, by Age K Units (2018-2023)
  • Table 221. MEA ADHD Treatment Sales, by Country K Units (2018-2023)
  • Table 222. MEA ADHD Treatment Sales, by Type K Units (2018-2023)
  • Table 223. MEA ADHD Treatment Sales, by Treatment K Units (2018-2023)
  • Table 224. MEA ADHD Treatment Sales, by End-User K Units (2018-2023)
  • Table 225. MEA ADHD Treatment Sales, by Age K Units (2018-2023)
  • Table 226. Middle East ADHD Treatment Sales, by Type K Units (2018-2023)
  • Table 227. Middle East ADHD Treatment Sales, by Treatment K Units (2018-2023)
  • Table 228. Middle East ADHD Treatment Sales, by End-User K Units (2018-2023)
  • Table 229. Middle East ADHD Treatment Sales, by Age K Units (2018-2023)
  • Table 230. Africa ADHD Treatment Sales, by Type K Units (2018-2023)
  • Table 231. Africa ADHD Treatment Sales, by Treatment K Units (2018-2023)
  • Table 232. Africa ADHD Treatment Sales, by End-User K Units (2018-2023)
  • Table 233. Africa ADHD Treatment Sales, by Age K Units (2018-2023)
  • Table 234. North America ADHD Treatment Sales, by Country K Units (2018-2023)
  • Table 235. North America ADHD Treatment Sales, by Type K Units (2018-2023)
  • Table 236. North America ADHD Treatment Sales, by Treatment K Units (2018-2023)
  • Table 237. North America ADHD Treatment Sales, by End-User K Units (2018-2023)
  • Table 238. North America ADHD Treatment Sales, by Age K Units (2018-2023)
  • Table 239. United States ADHD Treatment Sales, by Type K Units (2018-2023)
  • Table 240. United States ADHD Treatment Sales, by Treatment K Units (2018-2023)
  • Table 241. United States ADHD Treatment Sales, by End-User K Units (2018-2023)
  • Table 242. United States ADHD Treatment Sales, by Age K Units (2018-2023)
  • Table 243. Canada ADHD Treatment Sales, by Type K Units (2018-2023)
  • Table 244. Canada ADHD Treatment Sales, by Treatment K Units (2018-2023)
  • Table 245. Canada ADHD Treatment Sales, by End-User K Units (2018-2023)
  • Table 246. Canada ADHD Treatment Sales, by Age K Units (2018-2023)
  • Table 247. Mexico ADHD Treatment Sales, by Type K Units (2018-2023)
  • Table 248. Mexico ADHD Treatment Sales, by Treatment K Units (2018-2023)
  • Table 249. Mexico ADHD Treatment Sales, by End-User K Units (2018-2023)
  • Table 250. Mexico ADHD Treatment Sales, by Age K Units (2018-2023)
  • Table 251. ADHD Treatment: by Type(USD/Units)
  • Table 252. Company Basic Information, Sales Area and Its Competitors
  • Table 253. Company Basic Information, Sales Area and Its Competitors
  • Table 254. Company Basic Information, Sales Area and Its Competitors
  • Table 255. Company Basic Information, Sales Area and Its Competitors
  • Table 256. Company Basic Information, Sales Area and Its Competitors
  • Table 257. Company Basic Information, Sales Area and Its Competitors
  • Table 258. Company Basic Information, Sales Area and Its Competitors
  • Table 259. Company Basic Information, Sales Area and Its Competitors
  • Table 260. Company Basic Information, Sales Area and Its Competitors
  • Table 261. Company Basic Information, Sales Area and Its Competitors
  • Table 262. ADHD Treatment: by Type(USD Million)
  • Table 263. ADHD Treatment Methylphenidate , by Region USD Million (2025-2030)
  • Table 264. ADHD Treatment Lisdexamfetamine , by Region USD Million (2025-2030)
  • Table 265. ADHD Treatment Dexamfetamine , by Region USD Million (2025-2030)
  • Table 266. ADHD Treatment Atomoxetine , by Region USD Million (2025-2030)
  • Table 267. ADHD Treatment Guanfacine , by Region USD Million (2025-2030)
  • Table 268. ADHD Treatment Others , by Region USD Million (2025-2030)
  • Table 269. ADHD Treatment: by Treatment(USD Million)
  • Table 270. ADHD Treatment Medications , by Region USD Million (2025-2030)
  • Table 271. ADHD Treatment Behavior Therapy , by Region USD Million (2025-2030)
  • Table 272. ADHD Treatment Counselling , by Region USD Million (2025-2030)
  • Table 273. ADHD Treatment Education Services , by Region USD Million (2025-2030)
  • Table 274. ADHD Treatment Others , by Region USD Million (2025-2030)
  • Table 275. ADHD Treatment: by End-User(USD Million)
  • Table 276. ADHD Treatment Retail Pharmacy , by Region USD Million (2025-2030)
  • Table 277. ADHD Treatment Hospital Pharmacy , by Region USD Million (2025-2030)
  • Table 278. ADHD Treatment Clinics , by Region USD Million (2025-2030)
  • Table 279. ADHD Treatment: by Age(USD Million)
  • Table 280. ADHD Treatment Adult (Aged 18 and above) , by Region USD Million (2025-2030)
  • Table 281. ADHD Treatment Children , by Region USD Million (2025-2030)
  • Table 282. South America ADHD Treatment, by Country USD Million (2025-2030)
  • Table 283. South America ADHD Treatment, by Type USD Million (2025-2030)
  • Table 284. South America ADHD Treatment, by Treatment USD Million (2025-2030)
  • Table 285. South America ADHD Treatment, by End-User USD Million (2025-2030)
  • Table 286. South America ADHD Treatment, by Age USD Million (2025-2030)
  • Table 287. Brazil ADHD Treatment, by Type USD Million (2025-2030)
  • Table 288. Brazil ADHD Treatment, by Treatment USD Million (2025-2030)
  • Table 289. Brazil ADHD Treatment, by End-User USD Million (2025-2030)
  • Table 290. Brazil ADHD Treatment, by Age USD Million (2025-2030)
  • Table 291. Argentina ADHD Treatment, by Type USD Million (2025-2030)
  • Table 292. Argentina ADHD Treatment, by Treatment USD Million (2025-2030)
  • Table 293. Argentina ADHD Treatment, by End-User USD Million (2025-2030)
  • Table 294. Argentina ADHD Treatment, by Age USD Million (2025-2030)
  • Table 295. Rest of South America ADHD Treatment, by Type USD Million (2025-2030)
  • Table 296. Rest of South America ADHD Treatment, by Treatment USD Million (2025-2030)
  • Table 297. Rest of South America ADHD Treatment, by End-User USD Million (2025-2030)
  • Table 298. Rest of South America ADHD Treatment, by Age USD Million (2025-2030)
  • Table 299. Asia Pacific ADHD Treatment, by Country USD Million (2025-2030)
  • Table 300. Asia Pacific ADHD Treatment, by Type USD Million (2025-2030)
  • Table 301. Asia Pacific ADHD Treatment, by Treatment USD Million (2025-2030)
  • Table 302. Asia Pacific ADHD Treatment, by End-User USD Million (2025-2030)
  • Table 303. Asia Pacific ADHD Treatment, by Age USD Million (2025-2030)
  • Table 304. China ADHD Treatment, by Type USD Million (2025-2030)
  • Table 305. China ADHD Treatment, by Treatment USD Million (2025-2030)
  • Table 306. China ADHD Treatment, by End-User USD Million (2025-2030)
  • Table 307. China ADHD Treatment, by Age USD Million (2025-2030)
  • Table 308. Japan ADHD Treatment, by Type USD Million (2025-2030)
  • Table 309. Japan ADHD Treatment, by Treatment USD Million (2025-2030)
  • Table 310. Japan ADHD Treatment, by End-User USD Million (2025-2030)
  • Table 311. Japan ADHD Treatment, by Age USD Million (2025-2030)
  • Table 312. India ADHD Treatment, by Type USD Million (2025-2030)
  • Table 313. India ADHD Treatment, by Treatment USD Million (2025-2030)
  • Table 314. India ADHD Treatment, by End-User USD Million (2025-2030)
  • Table 315. India ADHD Treatment, by Age USD Million (2025-2030)
  • Table 316. South Korea ADHD Treatment, by Type USD Million (2025-2030)
  • Table 317. South Korea ADHD Treatment, by Treatment USD Million (2025-2030)
  • Table 318. South Korea ADHD Treatment, by End-User USD Million (2025-2030)
  • Table 319. South Korea ADHD Treatment, by Age USD Million (2025-2030)
  • Table 320. Australia ADHD Treatment, by Type USD Million (2025-2030)
  • Table 321. Australia ADHD Treatment, by Treatment USD Million (2025-2030)
  • Table 322. Australia ADHD Treatment, by End-User USD Million (2025-2030)
  • Table 323. Australia ADHD Treatment, by Age USD Million (2025-2030)
  • Table 324. Rest of Asia-Pacific ADHD Treatment, by Type USD Million (2025-2030)
  • Table 325. Rest of Asia-Pacific ADHD Treatment, by Treatment USD Million (2025-2030)
  • Table 326. Rest of Asia-Pacific ADHD Treatment, by End-User USD Million (2025-2030)
  • Table 327. Rest of Asia-Pacific ADHD Treatment, by Age USD Million (2025-2030)
  • Table 328. Europe ADHD Treatment, by Country USD Million (2025-2030)
  • Table 329. Europe ADHD Treatment, by Type USD Million (2025-2030)
  • Table 330. Europe ADHD Treatment, by Treatment USD Million (2025-2030)
  • Table 331. Europe ADHD Treatment, by End-User USD Million (2025-2030)
  • Table 332. Europe ADHD Treatment, by Age USD Million (2025-2030)
  • Table 333. Germany ADHD Treatment, by Type USD Million (2025-2030)
  • Table 334. Germany ADHD Treatment, by Treatment USD Million (2025-2030)
  • Table 335. Germany ADHD Treatment, by End-User USD Million (2025-2030)
  • Table 336. Germany ADHD Treatment, by Age USD Million (2025-2030)
  • Table 337. France ADHD Treatment, by Type USD Million (2025-2030)
  • Table 338. France ADHD Treatment, by Treatment USD Million (2025-2030)
  • Table 339. France ADHD Treatment, by End-User USD Million (2025-2030)
  • Table 340. France ADHD Treatment, by Age USD Million (2025-2030)
  • Table 341. Italy ADHD Treatment, by Type USD Million (2025-2030)
  • Table 342. Italy ADHD Treatment, by Treatment USD Million (2025-2030)
  • Table 343. Italy ADHD Treatment, by End-User USD Million (2025-2030)
  • Table 344. Italy ADHD Treatment, by Age USD Million (2025-2030)
  • Table 345. United Kingdom ADHD Treatment, by Type USD Million (2025-2030)
  • Table 346. United Kingdom ADHD Treatment, by Treatment USD Million (2025-2030)
  • Table 347. United Kingdom ADHD Treatment, by End-User USD Million (2025-2030)
  • Table 348. United Kingdom ADHD Treatment, by Age USD Million (2025-2030)
  • Table 349. Netherlands ADHD Treatment, by Type USD Million (2025-2030)
  • Table 350. Netherlands ADHD Treatment, by Treatment USD Million (2025-2030)
  • Table 351. Netherlands ADHD Treatment, by End-User USD Million (2025-2030)
  • Table 352. Netherlands ADHD Treatment, by Age USD Million (2025-2030)
  • Table 353. Rest of Europe ADHD Treatment, by Type USD Million (2025-2030)
  • Table 354. Rest of Europe ADHD Treatment, by Treatment USD Million (2025-2030)
  • Table 355. Rest of Europe ADHD Treatment, by End-User USD Million (2025-2030)
  • Table 356. Rest of Europe ADHD Treatment, by Age USD Million (2025-2030)
  • Table 357. MEA ADHD Treatment, by Country USD Million (2025-2030)
  • Table 358. MEA ADHD Treatment, by Type USD Million (2025-2030)
  • Table 359. MEA ADHD Treatment, by Treatment USD Million (2025-2030)
  • Table 360. MEA ADHD Treatment, by End-User USD Million (2025-2030)
  • Table 361. MEA ADHD Treatment, by Age USD Million (2025-2030)
  • Table 362. Middle East ADHD Treatment, by Type USD Million (2025-2030)
  • Table 363. Middle East ADHD Treatment, by Treatment USD Million (2025-2030)
  • Table 364. Middle East ADHD Treatment, by End-User USD Million (2025-2030)
  • Table 365. Middle East ADHD Treatment, by Age USD Million (2025-2030)
  • Table 366. Africa ADHD Treatment, by Type USD Million (2025-2030)
  • Table 367. Africa ADHD Treatment, by Treatment USD Million (2025-2030)
  • Table 368. Africa ADHD Treatment, by End-User USD Million (2025-2030)
  • Table 369. Africa ADHD Treatment, by Age USD Million (2025-2030)
  • Table 370. North America ADHD Treatment, by Country USD Million (2025-2030)
  • Table 371. North America ADHD Treatment, by Type USD Million (2025-2030)
  • Table 372. North America ADHD Treatment, by Treatment USD Million (2025-2030)
  • Table 373. North America ADHD Treatment, by End-User USD Million (2025-2030)
  • Table 374. North America ADHD Treatment, by Age USD Million (2025-2030)
  • Table 375. United States ADHD Treatment, by Type USD Million (2025-2030)
  • Table 376. United States ADHD Treatment, by Treatment USD Million (2025-2030)
  • Table 377. United States ADHD Treatment, by End-User USD Million (2025-2030)
  • Table 378. United States ADHD Treatment, by Age USD Million (2025-2030)
  • Table 379. Canada ADHD Treatment, by Type USD Million (2025-2030)
  • Table 380. Canada ADHD Treatment, by Treatment USD Million (2025-2030)
  • Table 381. Canada ADHD Treatment, by End-User USD Million (2025-2030)
  • Table 382. Canada ADHD Treatment, by Age USD Million (2025-2030)
  • Table 383. Mexico ADHD Treatment, by Type USD Million (2025-2030)
  • Table 384. Mexico ADHD Treatment, by Treatment USD Million (2025-2030)
  • Table 385. Mexico ADHD Treatment, by End-User USD Million (2025-2030)
  • Table 386. Mexico ADHD Treatment, by Age USD Million (2025-2030)
  • Table 387. ADHD Treatment Sales: by Type(K Units)
  • Table 388. ADHD Treatment Sales Methylphenidate , by Region K Units (2025-2030)
  • Table 389. ADHD Treatment Sales Lisdexamfetamine , by Region K Units (2025-2030)
  • Table 390. ADHD Treatment Sales Dexamfetamine , by Region K Units (2025-2030)
  • Table 391. ADHD Treatment Sales Atomoxetine , by Region K Units (2025-2030)
  • Table 392. ADHD Treatment Sales Guanfacine , by Region K Units (2025-2030)
  • Table 393. ADHD Treatment Sales Others , by Region K Units (2025-2030)
  • Table 394. ADHD Treatment Sales: by Treatment(K Units)
  • Table 395. ADHD Treatment Sales Medications , by Region K Units (2025-2030)
  • Table 396. ADHD Treatment Sales Behavior Therapy , by Region K Units (2025-2030)
  • Table 397. ADHD Treatment Sales Counselling , by Region K Units (2025-2030)
  • Table 398. ADHD Treatment Sales Education Services , by Region K Units (2025-2030)
  • Table 399. ADHD Treatment Sales Others , by Region K Units (2025-2030)
  • Table 400. ADHD Treatment Sales: by End-User(K Units)
  • Table 401. ADHD Treatment Sales Retail Pharmacy , by Region K Units (2025-2030)
  • Table 402. ADHD Treatment Sales Hospital Pharmacy , by Region K Units (2025-2030)
  • Table 403. ADHD Treatment Sales Clinics , by Region K Units (2025-2030)
  • Table 404. ADHD Treatment Sales: by Age(K Units)
  • Table 405. ADHD Treatment Sales Adult (Aged 18 and above) , by Region K Units (2025-2030)
  • Table 406. ADHD Treatment Sales Children , by Region K Units (2025-2030)
  • Table 407. South America ADHD Treatment Sales, by Country K Units (2025-2030)
  • Table 408. South America ADHD Treatment Sales, by Type K Units (2025-2030)
  • Table 409. South America ADHD Treatment Sales, by Treatment K Units (2025-2030)
  • Table 410. South America ADHD Treatment Sales, by End-User K Units (2025-2030)
  • Table 411. South America ADHD Treatment Sales, by Age K Units (2025-2030)
  • Table 412. Brazil ADHD Treatment Sales, by Type K Units (2025-2030)
  • Table 413. Brazil ADHD Treatment Sales, by Treatment K Units (2025-2030)
  • Table 414. Brazil ADHD Treatment Sales, by End-User K Units (2025-2030)
  • Table 415. Brazil ADHD Treatment Sales, by Age K Units (2025-2030)
  • Table 416. Argentina ADHD Treatment Sales, by Type K Units (2025-2030)
  • Table 417. Argentina ADHD Treatment Sales, by Treatment K Units (2025-2030)
  • Table 418. Argentina ADHD Treatment Sales, by End-User K Units (2025-2030)
  • Table 419. Argentina ADHD Treatment Sales, by Age K Units (2025-2030)
  • Table 420. Rest of South America ADHD Treatment Sales, by Type K Units (2025-2030)
  • Table 421. Rest of South America ADHD Treatment Sales, by Treatment K Units (2025-2030)
  • Table 422. Rest of South America ADHD Treatment Sales, by End-User K Units (2025-2030)
  • Table 423. Rest of South America ADHD Treatment Sales, by Age K Units (2025-2030)
  • Table 424. Asia Pacific ADHD Treatment Sales, by Country K Units (2025-2030)
  • Table 425. Asia Pacific ADHD Treatment Sales, by Type K Units (2025-2030)
  • Table 426. Asia Pacific ADHD Treatment Sales, by Treatment K Units (2025-2030)
  • Table 427. Asia Pacific ADHD Treatment Sales, by End-User K Units (2025-2030)
  • Table 428. Asia Pacific ADHD Treatment Sales, by Age K Units (2025-2030)
  • Table 429. China ADHD Treatment Sales, by Type K Units (2025-2030)
  • Table 430. China ADHD Treatment Sales, by Treatment K Units (2025-2030)
  • Table 431. China ADHD Treatment Sales, by End-User K Units (2025-2030)
  • Table 432. China ADHD Treatment Sales, by Age K Units (2025-2030)
  • Table 433. Japan ADHD Treatment Sales, by Type K Units (2025-2030)
  • Table 434. Japan ADHD Treatment Sales, by Treatment K Units (2025-2030)
  • Table 435. Japan ADHD Treatment Sales, by End-User K Units (2025-2030)
  • Table 436. Japan ADHD Treatment Sales, by Age K Units (2025-2030)
  • Table 437. India ADHD Treatment Sales, by Type K Units (2025-2030)
  • Table 438. India ADHD Treatment Sales, by Treatment K Units (2025-2030)
  • Table 439. India ADHD Treatment Sales, by End-User K Units (2025-2030)
  • Table 440. India ADHD Treatment Sales, by Age K Units (2025-2030)
  • Table 441. South Korea ADHD Treatment Sales, by Type K Units (2025-2030)
  • Table 442. South Korea ADHD Treatment Sales, by Treatment K Units (2025-2030)
  • Table 443. South Korea ADHD Treatment Sales, by End-User K Units (2025-2030)
  • Table 444. South Korea ADHD Treatment Sales, by Age K Units (2025-2030)
  • Table 445. Australia ADHD Treatment Sales, by Type K Units (2025-2030)
  • Table 446. Australia ADHD Treatment Sales, by Treatment K Units (2025-2030)
  • Table 447. Australia ADHD Treatment Sales, by End-User K Units (2025-2030)
  • Table 448. Australia ADHD Treatment Sales, by Age K Units (2025-2030)
  • Table 449. Rest of Asia-Pacific ADHD Treatment Sales, by Type K Units (2025-2030)
  • Table 450. Rest of Asia-Pacific ADHD Treatment Sales, by Treatment K Units (2025-2030)
  • Table 451. Rest of Asia-Pacific ADHD Treatment Sales, by End-User K Units (2025-2030)
  • Table 452. Rest of Asia-Pacific ADHD Treatment Sales, by Age K Units (2025-2030)
  • Table 453. Europe ADHD Treatment Sales, by Country K Units (2025-2030)
  • Table 454. Europe ADHD Treatment Sales, by Type K Units (2025-2030)
  • Table 455. Europe ADHD Treatment Sales, by Treatment K Units (2025-2030)
  • Table 456. Europe ADHD Treatment Sales, by End-User K Units (2025-2030)
  • Table 457. Europe ADHD Treatment Sales, by Age K Units (2025-2030)
  • Table 458. Germany ADHD Treatment Sales, by Type K Units (2025-2030)
  • Table 459. Germany ADHD Treatment Sales, by Treatment K Units (2025-2030)
  • Table 460. Germany ADHD Treatment Sales, by End-User K Units (2025-2030)
  • Table 461. Germany ADHD Treatment Sales, by Age K Units (2025-2030)
  • Table 462. France ADHD Treatment Sales, by Type K Units (2025-2030)
  • Table 463. France ADHD Treatment Sales, by Treatment K Units (2025-2030)
  • Table 464. France ADHD Treatment Sales, by End-User K Units (2025-2030)
  • Table 465. France ADHD Treatment Sales, by Age K Units (2025-2030)
  • Table 466. Italy ADHD Treatment Sales, by Type K Units (2025-2030)
  • Table 467. Italy ADHD Treatment Sales, by Treatment K Units (2025-2030)
  • Table 468. Italy ADHD Treatment Sales, by End-User K Units (2025-2030)
  • Table 469. Italy ADHD Treatment Sales, by Age K Units (2025-2030)
  • Table 470. United Kingdom ADHD Treatment Sales, by Type K Units (2025-2030)
  • Table 471. United Kingdom ADHD Treatment Sales, by Treatment K Units (2025-2030)
  • Table 472. United Kingdom ADHD Treatment Sales, by End-User K Units (2025-2030)
  • Table 473. United Kingdom ADHD Treatment Sales, by Age K Units (2025-2030)
  • Table 474. Netherlands ADHD Treatment Sales, by Type K Units (2025-2030)
  • Table 475. Netherlands ADHD Treatment Sales, by Treatment K Units (2025-2030)
  • Table 476. Netherlands ADHD Treatment Sales, by End-User K Units (2025-2030)
  • Table 477. Netherlands ADHD Treatment Sales, by Age K Units (2025-2030)
  • Table 478. Rest of Europe ADHD Treatment Sales, by Type K Units (2025-2030)
  • Table 479. Rest of Europe ADHD Treatment Sales, by Treatment K Units (2025-2030)
  • Table 480. Rest of Europe ADHD Treatment Sales, by End-User K Units (2025-2030)
  • Table 481. Rest of Europe ADHD Treatment Sales, by Age K Units (2025-2030)
  • Table 482. MEA ADHD Treatment Sales, by Country K Units (2025-2030)
  • Table 483. MEA ADHD Treatment Sales, by Type K Units (2025-2030)
  • Table 484. MEA ADHD Treatment Sales, by Treatment K Units (2025-2030)
  • Table 485. MEA ADHD Treatment Sales, by End-User K Units (2025-2030)
  • Table 486. MEA ADHD Treatment Sales, by Age K Units (2025-2030)
  • Table 487. Middle East ADHD Treatment Sales, by Type K Units (2025-2030)
  • Table 488. Middle East ADHD Treatment Sales, by Treatment K Units (2025-2030)
  • Table 489. Middle East ADHD Treatment Sales, by End-User K Units (2025-2030)
  • Table 490. Middle East ADHD Treatment Sales, by Age K Units (2025-2030)
  • Table 491. Africa ADHD Treatment Sales, by Type K Units (2025-2030)
  • Table 492. Africa ADHD Treatment Sales, by Treatment K Units (2025-2030)
  • Table 493. Africa ADHD Treatment Sales, by End-User K Units (2025-2030)
  • Table 494. Africa ADHD Treatment Sales, by Age K Units (2025-2030)
  • Table 495. North America ADHD Treatment Sales, by Country K Units (2025-2030)
  • Table 496. North America ADHD Treatment Sales, by Type K Units (2025-2030)
  • Table 497. North America ADHD Treatment Sales, by Treatment K Units (2025-2030)
  • Table 498. North America ADHD Treatment Sales, by End-User K Units (2025-2030)
  • Table 499. North America ADHD Treatment Sales, by Age K Units (2025-2030)
  • Table 500. United States ADHD Treatment Sales, by Type K Units (2025-2030)
  • Table 501. United States ADHD Treatment Sales, by Treatment K Units (2025-2030)
  • Table 502. United States ADHD Treatment Sales, by End-User K Units (2025-2030)
  • Table 503. United States ADHD Treatment Sales, by Age K Units (2025-2030)
  • Table 504. Canada ADHD Treatment Sales, by Type K Units (2025-2030)
  • Table 505. Canada ADHD Treatment Sales, by Treatment K Units (2025-2030)
  • Table 506. Canada ADHD Treatment Sales, by End-User K Units (2025-2030)
  • Table 507. Canada ADHD Treatment Sales, by Age K Units (2025-2030)
  • Table 508. Mexico ADHD Treatment Sales, by Type K Units (2025-2030)
  • Table 509. Mexico ADHD Treatment Sales, by Treatment K Units (2025-2030)
  • Table 510. Mexico ADHD Treatment Sales, by End-User K Units (2025-2030)
  • Table 511. Mexico ADHD Treatment Sales, by Age K Units (2025-2030)
  • Table 512. ADHD Treatment: by Type(USD/Units)
  • Table 513. Research Programs/Design for This Report
  • Table 514. Key Data Information from Secondary Sources
  • Table 515. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global ADHD Treatment: by Type USD Million (2018-2023)
  • Figure 5. Global ADHD Treatment: by Treatment USD Million (2018-2023)
  • Figure 6. Global ADHD Treatment: by End-User USD Million (2018-2023)
  • Figure 7. Global ADHD Treatment: by Age USD Million (2018-2023)
  • Figure 8. South America ADHD Treatment Share (%), by Country
  • Figure 9. Asia Pacific ADHD Treatment Share (%), by Country
  • Figure 10. Europe ADHD Treatment Share (%), by Country
  • Figure 11. MEA ADHD Treatment Share (%), by Country
  • Figure 12. North America ADHD Treatment Share (%), by Country
  • Figure 13. Global ADHD Treatment: by Type K Units (2018-2023)
  • Figure 14. Global ADHD Treatment: by Treatment K Units (2018-2023)
  • Figure 15. Global ADHD Treatment: by End-User K Units (2018-2023)
  • Figure 16. Global ADHD Treatment: by Age K Units (2018-2023)
  • Figure 17. South America ADHD Treatment Share (%), by Country
  • Figure 18. Asia Pacific ADHD Treatment Share (%), by Country
  • Figure 19. Europe ADHD Treatment Share (%), by Country
  • Figure 20. MEA ADHD Treatment Share (%), by Country
  • Figure 21. North America ADHD Treatment Share (%), by Country
  • Figure 22. Global ADHD Treatment: by Type USD/Units (2018-2023)
  • Figure 23. Global ADHD Treatment share by Players 2023 (%)
  • Figure 24. Global ADHD Treatment share by Players (Top 3) 2023(%)
  • Figure 25. Global ADHD Treatment share by Players (Top 5) 2023(%)
  • Figure 26. BCG Matrix for key Companies
  • Figure 27. Amneal Pharmaceuticals, Inc (United States) Revenue, Net Income and Gross profit
  • Figure 28. Amneal Pharmaceuticals, Inc (United States) Revenue: by Geography 2023
  • Figure 29. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 30. Eli Lilly and Company (United States) Revenue: by Geography 2023
  • Figure 31. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 32. Novartis International AG (Switzerland) Revenue: by Geography 2023
  • Figure 33. Janssen Pharmaceuticals, Inc (Belgium) Revenue, Net Income and Gross profit
  • Figure 34. Janssen Pharmaceuticals, Inc (Belgium) Revenue: by Geography 2023
  • Figure 35. Mayo Clinic (United States) Revenue, Net Income and Gross profit
  • Figure 36. Mayo Clinic (United States) Revenue: by Geography 2023
  • Figure 37. RespireRx Pharmaceuticals Inc (United States) Revenue, Net Income and Gross profit
  • Figure 38. RespireRx Pharmaceuticals Inc (United States) Revenue: by Geography 2023
  • Figure 39. Otsuka Pharmaceutical Co., Ltd (Japan) Revenue, Net Income and Gross profit
  • Figure 40. Otsuka Pharmaceutical Co., Ltd (Japan) Revenue: by Geography 2023
  • Figure 41. Neos Therapeutics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 42. Neos Therapeutics, Inc. (United States) Revenue: by Geography 2023
  • Figure 43. Takeda Pharmaceutical Company Limited (Japan) Revenue, Net Income and Gross profit
  • Figure 44. Takeda Pharmaceutical Company Limited (Japan) Revenue: by Geography 2023
  • Figure 45. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 46. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2023
  • Figure 47. Global ADHD Treatment: by Type USD Million (2025-2030)
  • Figure 48. Global ADHD Treatment: by Treatment USD Million (2025-2030)
  • Figure 49. Global ADHD Treatment: by End-User USD Million (2025-2030)
  • Figure 50. Global ADHD Treatment: by Age USD Million (2025-2030)
  • Figure 51. South America ADHD Treatment Share (%), by Country
  • Figure 52. Asia Pacific ADHD Treatment Share (%), by Country
  • Figure 53. Europe ADHD Treatment Share (%), by Country
  • Figure 54. MEA ADHD Treatment Share (%), by Country
  • Figure 55. North America ADHD Treatment Share (%), by Country
  • Figure 56. Global ADHD Treatment: by Type K Units (2025-2030)
  • Figure 57. Global ADHD Treatment: by Treatment K Units (2025-2030)
  • Figure 58. Global ADHD Treatment: by End-User K Units (2025-2030)
  • Figure 59. Global ADHD Treatment: by Age K Units (2025-2030)
  • Figure 60. South America ADHD Treatment Share (%), by Country
  • Figure 61. Asia Pacific ADHD Treatment Share (%), by Country
  • Figure 62. Europe ADHD Treatment Share (%), by Country
  • Figure 63. MEA ADHD Treatment Share (%), by Country
  • Figure 64. North America ADHD Treatment Share (%), by Country
  • Figure 65. Global ADHD Treatment: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Amneal Pharmaceuticals, Inc (United States)
  • Eli Lilly and Company (United States)
  • Novartis International AG (Switzerland)
  • Janssen Pharmaceuticals, Inc (Belgium)
  • Mayo Clinic (United States)
  • RespireRx Pharmaceuticals Inc (United States)
  • Otsuka Pharmaceutical Co., Ltd (Japan)
  • Neos Therapeutics, Inc. (United States)
  • Takeda Pharmaceutical Company Limited (Japan)
  • GlaxoSmithKline plc (United Kingdom)
Additional players considered in the study are as follows:
Noven Pharmaceuticals, Inc (United States) , Purdue Pharma L.P. (United States)
Select User Access Type

Key Highlights of Report


Mar 2024 202 Pages 65 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global ADHD Treatment Market Quantitative research analysis
Global ADHD Treatment Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Amneal Pharmaceuticals, Inc (United States), Eli Lilly and Company (United States), Novartis International AG (Switzerland), Janssen Pharmaceuticals, Inc (Belgium), Mayo Clinic (United States), RespireRx Pharmaceuticals Inc (United States), Otsuka Pharmaceutical Co., Ltd (Japan), Neos Therapeutics, Inc. (United States), Takeda Pharmaceutical Company Limited (Japan) and GlaxoSmithKline plc (United Kingdom) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increasing demand of Azstarys which is stimulant medication" is seen as one of major influencing trends for ADHD Treatment Market during projected period 2023-2030.
The ADHD Treatment market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global ADHD Treatment Market Report?

Have a Query? Click Here

Other Related Reports

Sensitive Toothcare Comprehensive Study by Type (Toothpaste, Mouthwash), Sales (Off-trade (supermarkets/hypermarkets) Players and Region - Global Market Outlook to 2027
$ 3400
Cellular Analysis Comprehensive Study by Type (Cell Microarrays, Flow Cytometry Products, HCS Systems, QPCR Products, Cell Counters, Others), Application (Stem Cell Research, Cancer Research, Tissue ...
$ 3800
Liposomal Supplement Comprehensive Study by Type (Vitamin C, Glutathione, Vitamin D, Curcumin, Others), Distribution channel (Online, Offline) Players and Region - Europe Market Outlook to 2030
$ 3400
Point-of-Care Diagnostics Kit Comprehensive Study by Type (Glucose Monitoring (Strips, Meters, and Lancets), Cardiometabolic testing, Infectious disease testing, Coagulation testing, Pregnancy and fe...
$ 3800
Cardiac Assist Devices Cad Comprehensive Study by Type (Ventricular assist devices, Intra-aortic balloon pumps (IABPs), Total artificial heart), Application (Bridge-to-transplant (BTT) therapy, Desti...
$ 3800
Eye Cancer Treatment Comprehensive Study by Type (Eyelid Tumor, Corneal Tumor, Uveal Melanoma, Orbital Tumor), Treatment (Surgery, Radiation Therapy, Laser Therapy, Chemotherapy, Others), End-User (...
$ 3500